Welcome to our dedicated page for Inogen news (Ticker: INGN), a resource for investors and traders seeking the latest updates and insights on Inogen stock.
News for Inogen Inc (INGN) centers on its activities as a medical technology company focused on respiratory products for homecare use. This page aggregates company press releases, earnings announcements, product launches, and other public updates that Inogen provides to investors, patients, and partners.
Inogen regularly issues quarterly financial results and outlook updates, detailing revenue by sales and rental categories, business-to-business and direct-to-consumer performance, gross margin trends, operating expenses, and non-GAAP measures such as EBITDA and adjusted EBITDA. These releases often highlight factors driving performance, such as demand from domestic and international business-to-business customers and changes in direct-to-consumer and rental revenue.
Product-related news is another key theme. Recent announcements include the launch of the Voxi 5 stationary oxygen concentrator, designed to expand access to oxygen therapy for long-term care patients in the United States, and the introduction of Aurora CPAP masks for patients with obstructive sleep apnea. Such updates illustrate how Inogen is broadening its respiratory care portfolio beyond portable oxygen concentrators into stationary oxygen therapy and sleep-therapy accessories.
Corporate and leadership developments, such as technology and executive appointments, also appear in Inogen’s news flow, offering context on how the company is organizing around digital health, connected devices, and operational execution. Investors and observers can use this news page to follow Inogen’s financial trajectory, portfolio evolution, and strategic priorities in home respiratory and sleep care.
For anyone tracking INGN stock, revisiting this page provides a consolidated view of Inogen’s latest earnings releases, conference call announcements, and product milestones, all drawn from the company’s own public communications.
Inogen, Inc. (Nasdaq: INGN) announced its participation in the 22nd Annual Needham Virtual Healthcare Conference on April 19, 2023, at 12:45 p.m. ET. The event will include a live audio webcast and an archived recording accessible via the News / Events section of Inogen's Investor Relations website. As a leader in the medical technology sector, Inogen specializes in innovative respiratory products for homecare settings, focusing on portable oxygen concentrators for chronic respiratory conditions. For more details, visit www.inogen.com.
Inogen, Inc. has appointed Tom West to its Board of Directors, effective April 1, 2023, while Kristen Miranda will retire on March 31, 2023. Tom West brings extensive experience from various leadership roles in the medical technology sector, including his recent position as CEO of Intersect ENT, Inc.. The Board's chair, Elizabeth Mora, emphasizes West's potential to enhance Inogen's strategic initiatives and operational efficiency. West expressed enthusiasm for driving growth at Inogen, which specializes in respiratory care products. This change is part of the company's efforts to strengthen its leadership amidst ongoing transformation.
Inogen, a medical technology company focused on innovative respiratory products, will participate in a virtual fireside chat at the KeyBanc Virtual Life Sciences & MedTech Investor Forum on March 21, 2023, at 2:15 p.m. Eastern Time. The chat aims to enhance engagement with investors and provide insights into Inogen's operations. A live audio webcast and an archived recording will be accessible through the company's Investor Relations website. Inogen specializes in portable oxygen concentrators, supporting patients with chronic respiratory conditions.
Inogen, Inc. (Nasdaq: INGN), a medical technology company specializing in respiratory products, will host a conference call on February 27, 2023, at 10:00 a.m. Eastern Time. President and CEO Nabil Shabshab and CFO Kristin Caltrider will discuss the company's commercial and innovation strategies. A live audio webcast and archived recording will be available on Inogen's Investor Relations website. Inogen aims to enhance patient respiratory care through innovative portable oxygen concentrators, partnering with various healthcare stakeholders to ensure accessibility and mobility for patients suffering from chronic respiratory conditions.
Inogen, a medical technology company, reported a 15.3% year-over-year revenue growth for Q4 2022, totaling $88.1 million, driven by increased rental revenue and business-to-business sales. However, the company faced a GAAP net loss of $56.6 million due to a one-time loss related to an intangible asset. For the full year 2022, total revenue rose 5.4% to $377.2 million, but GAAP net losses expanded to $83.8 million. Operating expenses surged 42.8% year-over-year, reflecting strategic investments. Despite challenges, Inogen aims to focus on its innovation pipeline for future growth.
Inogen, Inc. (Nasdaq: INGN) has achieved significant regulatory milestones, including EU MDR certification and FDA 510(k) clearance for its portable oxygen concentrators. The EU certification allows Inogen to market the Inogen One G4 and G5 in Europe, while the FDA clearance for the new Rove 4 model enhances its U.S. product lineup. The Rove 6 has already launched in Europe, with plans for the Rove 4 release in the U.S. in late 2023. These advancements affirm Inogen’s commitment to innovation in respiratory care for patients requiring oxygen therapy.
Inogen, Inc. (Nasdaq: INGN) has released preliminary revenue estimates for Q4 and full year 2022, projecting revenues between $87.5 million to $88.5 million for Q4, reflecting a year-over-year growth of 14.5% to 15.8%. For the full year, revenue estimates range from $376.7 million to $377.7 million, a growth of 5.2% to 5.5%. CEO Nabil Shabshab mentioned improved productivity as the DTC team's tenure increases, despite macroeconomic challenges. A conference call is scheduled for February 23, 2023, to discuss the financial results.
Inogen, Inc. (NASDAQ: INGN), a medical technology company specializing in respiratory products, has announced its participation in the 41st Annual J.P. Morgan Healthcare Conference. President and CEO Nabil Shabshab will present on January 11, 2023, at 10:30 a.m. PT. A live webcast of the presentation will be available on the Inogen Investor Relations website, where archived recordings can also be accessed. Inogen is known for its innovative portable oxygen concentrators designed for patients with chronic respiratory conditions.
Inogen, Inc. (NASDAQ: INGN) has announced participation in two upcoming investor conferences. Management will present at the Stifel 2022 Healthcare Conference on November 15 at 10:20 a.m. ET and the Piper Sandler 34th Annual Healthcare Conference on November 30 at 11:30 a.m. ET. A live webcast and archived recordings of both events will be accessible through the company’s Investor Relations website. Inogen specializes in homecare respiratory products, particularly portable oxygen concentrators.
Inogen reported a total revenue of $105.4 million for Q3 2022, marking a 13.2% increase year-over-year compared to $93.1 million in Q3 2021. On a constant currency basis, revenue growth was 14.5%. However, the company faced a GAAP net loss of $9.5 million and an adjusted net loss of $4.1 million. Total operating expenses rose 28.5% to $53.1 million. Despite these challenges, Inogen maintains a robust cash position of $209.6 million with no debt. For Q4 2022, revenue guidance is projected between $87 million and $92 million, indicating a potential growth of 14% to 20%.